Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden

Huy Tram Nguyen, Nhung Nguyen, Liang Yen Liu, Laura Dovek, Daniel Lenchner, Robert Harris, Byram Ozer, Arliene Ravelo, Nicolas Sommer, Myung Shin Sim, Robert Elashoff, Richard Green, Phioanh Leia Nghiemphu, Timothy Francis Cloughesy, Benjamin Ellingson, Albert Lai

Research output: Contribution to journalArticle

Abstract

Background. Since its approval for use in recurrent glioblastoma (GBM), the survival benefit of bevacizumab (Bev) remains to be demonstrated. To address this issue, we retrospectively examined survival from first recurrence in patients treated with Bev, lomustine (CCNU), or Bev/CCNU. Methods. We identified 168 primary GBM patients diagnosed at UCLA and Kaiser Permanente LA who received upfront radio-chemotherapy, followed by Bev and/or CCNU at first recurrence. Three patient groups, contemporaneously diagnosed from 2009 through 2015, were identified: (1) patients treated with Bev alone (n = 49), (2) CCNU alone (CCNU 09-15) (n = 36), and (3) Bev/CCNU (n = 53). Another CCNU control group (n = 30) diagnosed from 2001 through 2004 (CCNU 01-04) was also derived. We measured tumor size at first recurrence treatment initiation, using bidimensional (2D) and volumetric (3D) techniques, and analyzed overall survival (OS) from first recurrence. Results. Among the entire cohort, larger tumor size at first recurrence was associated with poorer survival. The CCNU 01-04 group had similar tumor size as the Bev arms and low Bev crossover (7%). Treatment with Bev was associated with improved survival in patients with large tumor 2D measurements: Median OS for Bev and Bev/ CCNU groups were 6.71 mo (n = 27) and 6.97 mo (n = 36) vs 4.03 mo (n = 10) in CCNU 01-04. Analysis by 3D measurement yielded similar results. Interestingly, the CCNU 09-15 group showed the highest survival, likely due to smaller tumor size and crossover to Bev (69%). Conclusion. Survival advantage from Bev treatment was observed only among patients with large tumor burden as determined by either 2D or 3D measurement.

Original languageEnglish (US)
Pages (from-to)103-111
Number of pages9
JournalNeuro-Oncology Practice
Volume6
Issue number2
DOIs
StatePublished - Mar 29 2019
Externally publishedYes

Fingerprint

Lomustine
Glioblastoma
Tumor Burden
Radio
Recurrence
Drug Therapy
Survival
Neoplasms
Bevacizumab

Keywords

  • Bevacizumab
  • First recurrence
  • Glioblastoma
  • Overall
  • Survival
  • Tumor size

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. / Nguyen, Huy Tram; Nguyen, Nhung; Liu, Liang Yen; Dovek, Laura; Lenchner, Daniel; Harris, Robert; Ozer, Byram; Ravelo, Arliene; Sommer, Nicolas; Sim, Myung Shin; Elashoff, Robert; Green, Richard; Nghiemphu, Phioanh Leia; Cloughesy, Timothy Francis; Ellingson, Benjamin; Lai, Albert.

In: Neuro-Oncology Practice, Vol. 6, No. 2, 29.03.2019, p. 103-111.

Research output: Contribution to journalArticle

Nguyen, HT, Nguyen, N, Liu, LY, Dovek, L, Lenchner, D, Harris, R, Ozer, B, Ravelo, A, Sommer, N, Sim, MS, Elashoff, R, Green, R, Nghiemphu, PL, Cloughesy, TF, Ellingson, B & Lai, A 2019, 'Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden', Neuro-Oncology Practice, vol. 6, no. 2, pp. 103-111. https://doi.org/10.1093/nop/npy021
Nguyen, Huy Tram ; Nguyen, Nhung ; Liu, Liang Yen ; Dovek, Laura ; Lenchner, Daniel ; Harris, Robert ; Ozer, Byram ; Ravelo, Arliene ; Sommer, Nicolas ; Sim, Myung Shin ; Elashoff, Robert ; Green, Richard ; Nghiemphu, Phioanh Leia ; Cloughesy, Timothy Francis ; Ellingson, Benjamin ; Lai, Albert. / Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. In: Neuro-Oncology Practice. 2019 ; Vol. 6, No. 2. pp. 103-111.
@article{5adb979a455445b793e0ab583061d53b,
title = "Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden",
abstract = "Background. Since its approval for use in recurrent glioblastoma (GBM), the survival benefit of bevacizumab (Bev) remains to be demonstrated. To address this issue, we retrospectively examined survival from first recurrence in patients treated with Bev, lomustine (CCNU), or Bev/CCNU. Methods. We identified 168 primary GBM patients diagnosed at UCLA and Kaiser Permanente LA who received upfront radio-chemotherapy, followed by Bev and/or CCNU at first recurrence. Three patient groups, contemporaneously diagnosed from 2009 through 2015, were identified: (1) patients treated with Bev alone (n = 49), (2) CCNU alone (CCNU 09-15) (n = 36), and (3) Bev/CCNU (n = 53). Another CCNU control group (n = 30) diagnosed from 2001 through 2004 (CCNU 01-04) was also derived. We measured tumor size at first recurrence treatment initiation, using bidimensional (2D) and volumetric (3D) techniques, and analyzed overall survival (OS) from first recurrence. Results. Among the entire cohort, larger tumor size at first recurrence was associated with poorer survival. The CCNU 01-04 group had similar tumor size as the Bev arms and low Bev crossover (7{\%}). Treatment with Bev was associated with improved survival in patients with large tumor 2D measurements: Median OS for Bev and Bev/ CCNU groups were 6.71 mo (n = 27) and 6.97 mo (n = 36) vs 4.03 mo (n = 10) in CCNU 01-04. Analysis by 3D measurement yielded similar results. Interestingly, the CCNU 09-15 group showed the highest survival, likely due to smaller tumor size and crossover to Bev (69{\%}). Conclusion. Survival advantage from Bev treatment was observed only among patients with large tumor burden as determined by either 2D or 3D measurement.",
keywords = "Bevacizumab, First recurrence, Glioblastoma, Overall, Survival, Tumor size",
author = "Nguyen, {Huy Tram} and Nhung Nguyen and Liu, {Liang Yen} and Laura Dovek and Daniel Lenchner and Robert Harris and Byram Ozer and Arliene Ravelo and Nicolas Sommer and Sim, {Myung Shin} and Robert Elashoff and Richard Green and Nghiemphu, {Phioanh Leia} and Cloughesy, {Timothy Francis} and Benjamin Ellingson and Albert Lai",
year = "2019",
month = "3",
day = "29",
doi = "10.1093/nop/npy021",
language = "English (US)",
volume = "6",
pages = "103--111",
journal = "Neuro-Oncology Practice",
issn = "2054-2577",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden

AU - Nguyen, Huy Tram

AU - Nguyen, Nhung

AU - Liu, Liang Yen

AU - Dovek, Laura

AU - Lenchner, Daniel

AU - Harris, Robert

AU - Ozer, Byram

AU - Ravelo, Arliene

AU - Sommer, Nicolas

AU - Sim, Myung Shin

AU - Elashoff, Robert

AU - Green, Richard

AU - Nghiemphu, Phioanh Leia

AU - Cloughesy, Timothy Francis

AU - Ellingson, Benjamin

AU - Lai, Albert

PY - 2019/3/29

Y1 - 2019/3/29

N2 - Background. Since its approval for use in recurrent glioblastoma (GBM), the survival benefit of bevacizumab (Bev) remains to be demonstrated. To address this issue, we retrospectively examined survival from first recurrence in patients treated with Bev, lomustine (CCNU), or Bev/CCNU. Methods. We identified 168 primary GBM patients diagnosed at UCLA and Kaiser Permanente LA who received upfront radio-chemotherapy, followed by Bev and/or CCNU at first recurrence. Three patient groups, contemporaneously diagnosed from 2009 through 2015, were identified: (1) patients treated with Bev alone (n = 49), (2) CCNU alone (CCNU 09-15) (n = 36), and (3) Bev/CCNU (n = 53). Another CCNU control group (n = 30) diagnosed from 2001 through 2004 (CCNU 01-04) was also derived. We measured tumor size at first recurrence treatment initiation, using bidimensional (2D) and volumetric (3D) techniques, and analyzed overall survival (OS) from first recurrence. Results. Among the entire cohort, larger tumor size at first recurrence was associated with poorer survival. The CCNU 01-04 group had similar tumor size as the Bev arms and low Bev crossover (7%). Treatment with Bev was associated with improved survival in patients with large tumor 2D measurements: Median OS for Bev and Bev/ CCNU groups were 6.71 mo (n = 27) and 6.97 mo (n = 36) vs 4.03 mo (n = 10) in CCNU 01-04. Analysis by 3D measurement yielded similar results. Interestingly, the CCNU 09-15 group showed the highest survival, likely due to smaller tumor size and crossover to Bev (69%). Conclusion. Survival advantage from Bev treatment was observed only among patients with large tumor burden as determined by either 2D or 3D measurement.

AB - Background. Since its approval for use in recurrent glioblastoma (GBM), the survival benefit of bevacizumab (Bev) remains to be demonstrated. To address this issue, we retrospectively examined survival from first recurrence in patients treated with Bev, lomustine (CCNU), or Bev/CCNU. Methods. We identified 168 primary GBM patients diagnosed at UCLA and Kaiser Permanente LA who received upfront radio-chemotherapy, followed by Bev and/or CCNU at first recurrence. Three patient groups, contemporaneously diagnosed from 2009 through 2015, were identified: (1) patients treated with Bev alone (n = 49), (2) CCNU alone (CCNU 09-15) (n = 36), and (3) Bev/CCNU (n = 53). Another CCNU control group (n = 30) diagnosed from 2001 through 2004 (CCNU 01-04) was also derived. We measured tumor size at first recurrence treatment initiation, using bidimensional (2D) and volumetric (3D) techniques, and analyzed overall survival (OS) from first recurrence. Results. Among the entire cohort, larger tumor size at first recurrence was associated with poorer survival. The CCNU 01-04 group had similar tumor size as the Bev arms and low Bev crossover (7%). Treatment with Bev was associated with improved survival in patients with large tumor 2D measurements: Median OS for Bev and Bev/ CCNU groups were 6.71 mo (n = 27) and 6.97 mo (n = 36) vs 4.03 mo (n = 10) in CCNU 01-04. Analysis by 3D measurement yielded similar results. Interestingly, the CCNU 09-15 group showed the highest survival, likely due to smaller tumor size and crossover to Bev (69%). Conclusion. Survival advantage from Bev treatment was observed only among patients with large tumor burden as determined by either 2D or 3D measurement.

KW - Bevacizumab

KW - First recurrence

KW - Glioblastoma

KW - Overall

KW - Survival

KW - Tumor size

UR - http://www.scopus.com/inward/record.url?scp=85064137226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064137226&partnerID=8YFLogxK

U2 - 10.1093/nop/npy021

DO - 10.1093/nop/npy021

M3 - Article

C2 - 31386050

AN - SCOPUS:85064137226

VL - 6

SP - 103

EP - 111

JO - Neuro-Oncology Practice

JF - Neuro-Oncology Practice

SN - 2054-2577

IS - 2

ER -